Phase III Study of Oral REVLIMID A in Newly-Diagnosed Multiple Myeloma Meets Primary Endpoint )--Celgene International SA rl, a wholly-owned subsidiary of Celgene Corporation , today announced that its phase III study of REVLIMIDA in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of ... (more)
http://eon.businesswire.com/news/eon/20130711005636/en/Phase-III-Study-MM-020IFM-07-01-Oral-REVLIMID%C2%AE
http://eon.businesswire.com/news/eon/20130711005636/en/Phase-III-Study-MM-020IFM-07-01-Oral-REVLIMID%C2%AE
No comments:
Post a Comment